Truveta Expands Global Engineering Footprint with Launch of New India Development Center in Hyderabad

Date:

Share post:

Truveta, a leading healthcare data and AI platform company, has officially announced the launch of its new India Development Center (IDC) located in Hyderabad. This strategic expansion marks a significant milestone in scaling the company’s global engineering and technological capabilities. 

The newly established Truveta IDC will serve as an extension of the company’s worldwide engineering organization. Working in close collaboration with teams based in the United States, the Hyderabad center will focus on engineering cutting-edge data, artificial intelligence, and software solutions. These advanced capabilities are designed to transform vast streams of real-world health data into actionable insights, evidence, and breakthrough medical discoveries aimed at advancing healthcare and improving patient lives globally.

The Hyderabad facility enables Truveta to accelerate innovation at scale by tapping into India’s rich pool of world-class technical and engineering talent. United under the company’s core mission of *“Saving Lives with Data,”* the expanding team in India will play a pivotal role in building and enhancing Truveta’snext-generation health data infrastructure.

“We are thrilled to welcome our growing team in India and establish our presence in Hyderabad,” the company shared. “This expansion strengthens our global capabilities and unites top-tier talent worldwide to drive healthcare innovation forward.”

With this expansion, Truveta reinforces its commitment to addressing critical healthcare challenges through advanced analytics, secure data integration, and purpose-driven AI innovation.

Written by: Pragna Biswas

Graphics by: Pramit Hazra

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related articles

ViiV Healthcare Advances HIV Care with Breakthrough Long-Acting Injectable Data at AIDS 2026

ViiV Healthcare, the global specialist HIV company majority-owned by GSK plc, announced landmark clinical, real-world, and pipeline data...

Wockhardt Launches “Wockhardt Antibiotic Academy” to Tackle Growing Threat of Multidrug Resistance in India

Wockhardt Limited announced the launch of the Wockhardt Antibiotic Academy, a national initiative dedicated to fostering patient-centric scientific dialogue...

Optimus Pharma Secures Regulatory Approval for Non-Steroidal Tapinarof Cream to Treat Plaque Psoriasis

Optimus Pharma, a leading Indian pharmaceutical manufacturer and subsidiary of Sekhmet Pharmaventures, announced that it has received regulatory...

Enhertu Shows Better Results Than Standard Treatment in Lung Cancer Trial

AstraZeneca and Daiichi Sankyo announced that their antibody-drug conjugate Enhertu (trastuzumabderuxtecan) has achieved a statistically significant and clinically meaningful improvement...